RAFAEL HOLDINGS, INC. Discontinued Operation, Tax Effect of Discontinued Operation
RAFAEL HOLDINGS, INC. (RFL) reported Discontinued Operation, Tax Effect of Discontinued Operation of $30.00 thousand for the 3-month period ending 2026-04-30, per its 10-Q filed 2026-06-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation · last filed 2026-06-11
- RAFAEL HOLDINGS, INC. discontinued operation, tax effect of discontinued operation for the quarter ending 2026-04-30 was $30.00K, a 7.14% increase year-over-year.
- RAFAEL HOLDINGS, INC. discontinued operation, tax effect of discontinued operation for the quarter ending 2026-01-31 was $29.00K, a 0.00% change year-over-year.
- RAFAEL HOLDINGS, INC. discontinued operation, tax effect of discontinued operation for the quarter ending 2025-10-31 was $30.00K, a 11.11% increase year-over-year.
- RAFAEL HOLDINGS, INC. discontinued operation, tax effect of discontinued operation for the quarter ending 2025-07-31 was $56.00K, a 107.41% increase year-over-year.
- RAFAEL HOLDINGS, INC. discontinued operation, tax effect of discontinued operation for fiscal 2025 was $140.00K, a 29.63% increase from fiscal 2024.
- RAFAEL HOLDINGS, INC. discontinued operation, tax effect of discontinued operation for fiscal 2024 was $108.00K, a 48.82% decline from fiscal 2023.
- RAFAEL HOLDINGS, INC. discontinued operation, tax effect of discontinued operation for fiscal 2023 was $211.00K.
| Period end | Discontinued Operation, Tax Effect of Discontinued Operation 2 month | Discontinued Operation, Tax Effect of Discontinued Operation 3 month | Discontinued Operation, Tax Effect of Discontinued Operation 6 month | Discontinued Operation, Tax Effect of Discontinued Operation 6 month as first filed | Discontinued Operation, Tax Effect of Discontinued Operation 9 month | Discontinued Operation, Tax Effect of Discontinued Operation 9 month as first filed | Discontinued Operation, Tax Effect of Discontinued Operation 12 month | Discontinued Operation, Tax Effect of Discontinued Operation 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | $30.00K 10-Q · filed 2026-06-11 | $59.00K derived: sum of 2 quarters · filed 2026-06-11 | $89.00K 10-Q · filed 2026-06-11 | $145.00K derived: sum of 4 quarters · filed 2026-06-11 | ||||
| 2026-01-31 | $29.00K 10-Q · filed 2026-03-16 | $59.00K 10-Q · filed 2026-03-16 | $115.00K derived: sum of 3 quarters · filed 2026-03-16 | $143.00K derived: sum of 4 quarters · filed 2026-06-11 | ||||
| 2025-10-31 | $30.00K 10-Q · filed 2025-12-12 | $86.00K derived: sum of 2 quarters · filed 2025-12-12 | $114.00K derived: sum of 3 quarters · filed 2026-06-11 | $143.00K derived: sum of 4 quarters · filed 2026-06-11 | ||||
| 2025-07-31 | $56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | $84.00K derived: sum of 2 quarters · filed 2026-06-11 | $113.00K derived: sum of 3 quarters · filed 2026-06-11 | $140.00K 10-K · filed 2025-10-29 | ||||
| 2025-04-30 | $28.00K 10-Q · filed 2026-06-11 | $57.00K derived: sum of 2 quarters · filed 2026-06-11 | $84.00K 10-Q · filed 2026-06-11 | $111.00K derived: sum of 4 quarters · filed 2026-06-11 | ||||
| 2025-01-31 | $29.00K 10-Q · filed 2026-03-16 | $56.00K 10-Q · filed 2026-03-16 | $83.00K derived: sum of 3 quarters · filed 2026-03-16 | $110.00K derived: sum of 4 quarters · filed 2026-03-16 | ||||
| 2024-10-31 | $27.00K 10-Q · filed 2025-12-12 | $54.00K derived: sum of 2 quarters · filed 2025-12-12 | $81.00K derived: sum of 3 quarters · filed 2025-12-12 | $108.00K derived: sum of 4 quarters · filed 2025-12-12 | ||||
| 2024-07-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | $54.00K derived: sum of 2 quarters · filed 2025-10-29 | $81.00K derived: sum of 3 quarters · filed 2025-10-29 | $108.00K 10-K · filed 2025-10-29 | ||||
| 2024-04-30 | $27.00K 10-Q · filed 2025-06-11 | $54.00K derived: sum of 2 quarters · filed 2025-06-11 | $81.00K 10-Q · filed 2025-06-11 | $136.00K derived: sum of 4 quarters · filed 2025-06-11 | ||||
| 2024-01-31 | $27.00K 10-Q · filed 2024-03-14 | $54.00K 10-Q · filed 2025-03-14 | $109.00K derived: sum of 3 quarters · filed 2024-12-20 | $136.00K derived: sum of 4 quarters · filed 2024-12-20 | ||||
| 2024-01-01 | $27.00K 10-Q · filed 2025-03-14 | |||||||
| 2023-10-31 | $27.00K 10-Q · filed 2024-12-11 | $82.00K derived: sum of 2 quarters · filed 2024-12-20 | $109.00K derived: sum of 3 quarters · filed 2024-12-20 | $136.00K derived: sum of 4 quarters · filed 2024-12-20 | ||||
| 2023-07-31 | $55.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | $82.00K derived: sum of 2 quarters · filed 2024-12-20 | $109.00K derived: sum of 3 quarters · filed 2024-12-20 | $211.00K 10-K/A · filed 2024-12-20 | $102.00K 10-K · filed 2023-10-30 | |||
| 2023-04-30 | $27.00K 10-Q · filed 2024-06-14 | $54.00K derived: sum of 2 quarters · filed 2024-06-14 | $156.00K 10-Q · filed 2024-06-14 | $6.54M 10-Q · filed 2023-06-13 | ||||
| 2023-01-31 | $27.00K 10-Q · filed 2024-03-14 | $156.00K 10-Q · filed 2024-03-14 | $6.54M 10-Q · filed 2023-03-14 | |||||
| 2022-10-31 | $6.70M 10-Q · filed 2022-12-13 | |||||||
| 2022-04-30 | -$565.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13 | -$1.07M derived: sum of 2 quarters · filed 2023-06-13 | -$1.62M 10-Q · filed 2023-06-13 | |||||
| 2022-01-31 | -$508.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-14 | -$1.05M 10-Q · filed 2023-03-14 | ||||||
| 2021-10-31 | -$543.00K 10-Q · filed 2022-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |